These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole. Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179 [TBL] [Abstract][Full Text] [Related]
10. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method. Moreira da Silva R; Oliveira LT; Silva Barcellos NM; de Souza J; de Lana M Antimicrob Agents Chemother; 2012 Jun; 56(6):3344-8. PubMed ID: 22450981 [TBL] [Abstract][Full Text] [Related]
11. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease. Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects. Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172 [TBL] [Abstract][Full Text] [Related]
13. A high-performance liquid chromatographic method for benznidazole quantitation in plasma of patients with Chagas disease. Guerrero L; Pinazo MJ; Posada E; Gascón J; Ribas J; Soy D Clin Chem Lab Med; 2011 Jan; 49(1):77-82. PubMed ID: 21083440 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial. Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523 [TBL] [Abstract][Full Text] [Related]
15. Tolerability and pharmacokinetics of ranolazine following single and multiple sustained-release doses in Chinese healthy adult volunteers: a randomized, open-label, Latin square design, phase I study. Tan QY; Li HD; Zhu RH; Zhang QZ; Zhang J; Peng WX Am J Cardiovasc Drugs; 2013 Feb; 13(1):17-25. PubMed ID: 23355361 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers. Wenzler E; Ellis-Grosse EJ; Rodvold KA Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630194 [TBL] [Abstract][Full Text] [Related]
18. Rapid and sensitive ultra-high-pressure liquid chromatography method for quantification of antichagasic benznidazole in plasma: application in a preclinical pharmacokinetic study. Davanço MG; de Campos ML; Peccinini RG Biomed Chromatogr; 2015 Jul; 29(7):1008-15. PubMed ID: 25424984 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres. Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423 [TBL] [Abstract][Full Text] [Related]